Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Klaus-Dieter Riedel"'
Autor:
Eliford Ngaimisi, Abiy Habtewold, Omary Minzi, Eyasu Makonnen, Sabina Mugusi, Wondwossen Amogne, Getnet Yimer, Klaus-Dieter Riedel, Mohammed Janabi, Getachew Aderaye, Ferdinand Mugusi, Leif Bertilsson, Eleni Aklillu, Juergen Burhenne
Publikováno v:
PLoS ONE, Vol 8, Iss 7, p e67946 (2013)
We evaluated the importance of ethnicity and pharmacogenetic variations in determining efavirenz pharmacokinetics, auto-induction and immunological outcomes in two African populations.ART naïve HIV patients from Ethiopia (n = 285) and Tanzania (n =
Externí odkaz:
https://doaj.org/article/7f75ff2c9c2f4058a19475eb59de4a58
Autor:
Sabina Mugusi, Eliford Ngaimisi, Mohamed Janabi, Omary Minzi, Muhammad Bakari, Klaus-Dieter Riedel, Juergen Burhenne, Lars Lindquist, Ferdinand Mugusi, Eric Sandstrom, Eleni Aklillu
Publikováno v:
PLoS ONE, Vol 7, Iss 7, p e40180 (2012)
To investigate the timing, incidence, clinical presentation, pharmacokinetics and pharmacogenetic predictors for antiretroviral and anti-tuberculosis drug induced liver injury (DILI) in HIV patients with or without TB co-infection.A total of 473 trea
Externí odkaz:
https://doaj.org/article/2e97b6cae71e4ef6bd97da19e862f8dc
Autor:
Getnet Yimer, Nobuhisa Ueda, Abiy Habtewold, Wondwossen Amogne, Akira Suda, Klaus-Dieter Riedel, Jürgen Burhenne, Getachew Aderaye, Lars Lindquist, Eyasu Makonnen, Eleni Aklillu
Publikováno v:
PLoS ONE, Vol 6, Iss 12, p e27810 (2011)
BackgroundImplication of pharmacogenetic variations and efavirenz pharmacokinetics in concomitant efavirenz based antiviral therapy and anti-tubercular drug induced liver injury (DILI) has not been yet studied. We performed a prospective case-control
Externí odkaz:
https://doaj.org/article/e1ce99c0bd4644399fbce95ac165a999
Autor:
Regina Hellwig, Yvonne Schweizer, Walter E. Haefeli, Johanna Weiss, Klaus-Dieter Riedel, Christoph Markert, Gerd Mikus, Theresia Wirsching, Juergen Burhenne
Publikováno v:
British Journal of Clinical Pharmacology. 77:141-148
Aims The aim of this study was to assess the effect of the cytochrome P450 (CYP) 3A4 and organic anion-transporting polypeptide (OATP) 1B1 inhibitor clarithromycin on the pharmacokinetics of bosentan. We also aimed to evaluate the impact of CYP2C9 an
Autor:
Barbara Grün, Michael K. Kiessling, Geraldine Rauch, Klaus-Dieter Riedel, Johanna Weiss, David Czock, Jürgen Burhenne, Walter E. Haefeli
Publikováno v:
British Journal of Clinical Pharmacology. 76:787-796
Aims Metformin pharmacokinetics depends on the presence and activity of membrane-bound drug transporters and may be affected by transport inhibitors. The aim of this study was to investigate the effects of trimethoprim on metformin pharmacokinetics a
Autor:
Johanna Weiss, Jürgen Burhenne, Gerlinde Egerer, Gerd Mikus, Klaus-Dieter Riedel, Marcus J. P. Geist
Publikováno v:
Journal of Antimicrobial Chemotherapy. 68:2592-2599
Objectives: Voriconazole exhibits non-linear pharmacokinetics in adults and is said to be mainly metabolized by CYP2C19 and CYP3A4 to voriconazole-N-oxide. The aim of this study was to obtain data on steady-state pharmacokinetics after dosing for at
Publikováno v:
British Journal of Clinical Pharmacology. 74:854-863
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • The analgesic activity of tilidine is mediated by its active metabolite, nortilidine, which easily penetrates the blood–brain barrier and binds to the µ-opioid receptor as a potent agonist. • Tilidine
Publikováno v:
Naunyn-Schmiedeberg's Archives of Pharmacology. 385:633-639
Tilidine exhibits the highest consumption of opioids in Germany. The prodrug is hepatically metabolised in a sequential N-demethylation reaction. Its primary metabolite nortilidine is a selective μ-opioid receptor agonist which can penetrate the blo
Autor:
David Czock, Gerd Mikus, Johanna Weiss, Klaus-Dieter Riedel, Jürgen Burhenne, Walter E. Haefeli, Arwa Hassan
Publikováno v:
Therapeutic Drug Monitoring. 33:86-93
Very low voriconazole concentrations are commonly observed during therapeutic drug monitoring. Possible mechanisms include inappropriate dose selection, rapid metabolism (as a result of genetic polymorphisms or enzyme induction), and also nonadherenc
Autor:
Juergen Burhenne, Martina Gronkowski, Kathrin Eisenlohr, Gerd Mikus, Klaus-Dieter Riedel, Gerlinde Egerer
Publikováno v:
British Journal of Clinical Pharmacology. 70:903-907
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Nausea and vomiting are the most distressing side-effects of a high dose melphalan regimen. • Aprepitant in addition to an antiemetic standard regimen has been reported to improve significantly both acut